Premenstrual Syndrome includes a bundle of different symptoms (more than 100, depending on the author) which cyclically appear before menstruation. Slight changes a couple of days before menses are usually considered normal. However, when symptoms span more than 5 days, they can cause severe disability not only for the patient, but for her family and social circle.
Even though there are many symptoms, the most common are pelvic pain, headaches, tension and breast hypersensitivity, mood swings (depression, irritability) known as Premenstrual Dysphoric Disorder, difficult in severe cases, so difficult that it is sometimes diagnosed and treated as Bipolar Disorder. These recurring symptoms and others, such as water retention, extreme libido changes (either excessive or none), intestinal transit alterations (chronic constipation), severe acne, fragile hair and brittle nails, etc., have traditionally been considered to be caused by hormonal level changes. However, most hormonal suppression based treatments have been proved ineffective, which leads to the existence of other causal factors involved in its ethiopathogenesis. Other symptoms, such as psoriatic outbreaks, lower back pain and sciatica or sleeping disorders, among others, can be secondary to premenstrual dysphoric disorder, and can be triggered by an immune system weakness or pain threshold decrease related to preexistent pathologies. Many cases are diagnosed as fibromyalgia and are only treated symptomatically.
Dr. Jorge Lolas Talhami, Chilean gynecologist, has dedicated over 40 years to the study and treatment of Severe Premenstrual Syndrome. His vast experience, with over two thousand patients treated, support the existence of an increased secretion of uterus inflammation mediator factors, particularly prostanglandins, as a consequence of chronic uterine alterations. Dr. Lolas’ novel approach proposes to inactivate the source of these inflammation mediator factors, particularly the cervix. The type of treatment to be applied will depend on severity of the case, as for the selected technique and treatment duration, which sometimes may take several months. The goal is to prevent the use of medications for symptomatic treatment (painkillers, anti-inflammatory, anti-depressants, diuretics, etc.), acting directly on the causal agent. Definitive cure rates using Lolas’ therapy exceed 90%, and many of his patients have shared their testimony of gratitude through their online informative platform (spanish). Dr. Lolas himself, as well as some of his patients, have participated in TV interviews (spanish), where his treatment has been proven to be useful. Dr. Lafaja has also been interviewed about her experience using this technique.
Sometimes, patients recognize the causal event for uterus inflammation, but in many cases, the cause remains unknown. Although not all chronic cervix inflammation patients will develop a Premenstrual Syndrome, some of them may experience hypersensitivity, either due to an over-expression of prostaglandin receptors, or due to yet unknown interactions with cycle hormones and other neurotransmitters involved in the pain threshold and mood regulation, which trigger the symptomatic cascade.